01—Abstract
Summary
Summary of the 10-K filed February 14, 2017. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a neurological and endocrine-focused biopharmaceutical company with no approved products to date.
As of December 31, 2016, it reported an accumulated deficit of approximately $1.1 billiona, cash, cash equivalents and investments of $350.8 million, and a net loss of $141.1 million, or $1.63 per share, for 2016. Revenue was $15.0 million in 2016, all of it event-based revenue from AbbVie tied to the start of Phase III uterine fibroids development for elagolix. The company expects to be unprofitable in 2017.
The company's near-term value rests on INGREZZA (valbenazine) for tardive dyskinesia, whose New Drug Application was submitted in August 2016 and accepted for priority review with a PDUFA target action date of April 11, 2017. Management plans to build a specialty sales force of approximately 140 professionals and expects general and administrative expenses to increase significantly in 2017 to support commercialization. Other programs include elagolix (partnered with AbbVie, with an endometriosis NDA targeted for Q3 2017), opicapone (licensed from BIAL in February 2017 for the US and Canada, with a $30 million upfront fee and up to $115 millionb in milestones), and early-stage Tourette syndrome, essential tremor and congenital adrenal hyperplasia programs.
Key risks include the FDA decision on INGREZZA, reliance on single-source suppliers and collaborators, pending litigation from Mount Sinai over the AbbVie sublicense, and the need for additional funding. Management believes existing resources will be sufficient for at least the next 12 months.
02—Key points
Key Highlights
- INGREZZA (valbenazine) NDA for tardive dyskinesia was accepted for priority review, with a PDUFA target action date of April 11, 2017; the company has never obtained FDA approval for a drug.
- Net loss of $141.1 million ($1.63 per share) for 2016, up from $88.9 million in 2015; accumulated deficit of approximately $1.1 billion at December 31, 2016.
- Total revenues of $15.0 million in 2016, consisting of event-based revenue from AbbVie for initiation of Phase III elagolix development in uterine fibroids, versus $19.8 million in 2015.
- Cash, cash equivalents and investments totaled $350.8 million at December 31, 2016, compared with $461.7 million a year earlier; net cash used in operating activities was $106.2 million in 2016.
- Research and development expense rose to $94.3 million in 2016 from $81.5 million; general and administrative expense rose to $68.1 million from $32.5 million, reflecting commercial launch preparation.
- Opicapone licensed from BIAL in February 2017 for the US and Canada, with a $30 million upfront license fee and up to $115 million in potential milestone payments.
- AbbVie expects to submit an NDA for elagolix in endometriosis in Q3 2017, which would trigger an anticipated $30 million event-based payment to the company.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 14, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $15.00M$19.77M | −24.1% |
| Cost of Revenue | $0$0 | — |
| Gross Profit | $15.00M$19.77M | −24.1% |
| R&D Expenses | $94.29M$81.49M | +15.7% |
| SG&A Expenses | $68.08M$32.48M | +109.6% |
| Operating Expenses | $162.37M$113.97M | +42.5% |
| Operating Income | -$147.37M-$94.20M | −56.4% |
| Interest Expense | $0$0 | — |
| Net Income | -$141.09M-$88.93M | −58.7% |
| EPS (Basic) | $-1.63$-1.05 | −55.2% |
| EPS (Diluted) | $-1.63$-1.05 | −55.2% |
| Shares Outstanding (Basic) | 86.71M84.50M | +2.6% |
| Shares Outstanding (Diluted) | 86.71M84.50M | +2.6% |
05—Questions
Frequently Asked Questions
What is the key near-term catalyst for Neurocrine investors?
The FDA's decision on the INGREZZA (valbenazine) New Drug Application for tardive dyskinesia, with a PDUFA target action date of April 11, 2017. The filing states that the company intends to commercialize INGREZZA in the US upon approval through a specialty sales force of approximately 140 professionals.
Is Neurocrine expected to become profitable soon?
No. The company states it does not expect to be profitable or generate positive operating cash flow for 2017 and expects a net loss in 2017, primarily due to significantly higher general and administrative expenses for INGREZZA commercialization.
How long will current capital resources last?
The company believes its existing capital resources, together with investment income and future payments under its strategic alliances, will be sufficient to satisfy its current and projected funding requirements for at least the next 12 months. It notes that additional equity or debt financing may be needed and that any equity financing would be dilutive.
What is the status of the Mount Sinai lawsuit?
Mount Sinai filed a complaint on December 1, 2015 alleging that Neurocrine breached a 1999 license agreement by sublicensing its technology to AbbVie, seeking unspecified damages, future sublicensing fees and attorney's fees. The company filed counterclaims alleging patent misuse, non-infringement and invalidity, and believes it has meritorious defenses but cannot predict the outcome or estimate any potential loss.
What are the main partnerships supporting the pipeline?
AbbVie partners on elagolix for endometriosis and uterine fibroids, with AbbVie responsible for development and commercialization costs and an upfront payment of $75 million received in 2010. Mitsubishi Tanabe licensed INGREZZA for Japan and select Asian markets in 2015 with a $30 million upfront payment. BIAL licensed opicapone for the US and Canada in February 2017.
06—Continue